Buranakitjaroen, PeeraPhoojaroenchanachai, MetaSaravich, SurachaiSangprasert, Pantip2009-05-272009-05-272002-09-27Buranakitjaroen P, Phoojaroenchanachai M, Saravich S, Sangprasert P. The efficacy and tolerability of an angiotensin II receptor blocker, telmisartan, in Thai patients with mild to moderate essential hypertension. Journal of the Medical Association of Thailand. 2002 Sep; 85(9): 968-77http://imsear.searo.who.int/handle/123456789/41950Chotmaihet Thangphaet.This open-labeled single-blinded study was performed to evaluate the efficacy and tolerability of telmisartan in the treatment of mild to moderate essential hypertension. Each patient was assigned to take a placebo for 4 weeks followed by once daily-titrated telmisartan (40-80 mg) for 8 weeks. "Office BP" and "24-hour ambulatory BP" measurements (24-h ABPM) were recorded as scheduled. Thirty-one patients (10 males: 21 females) with a mean age of 48.1 years were enrolled. The final SBP/DBP reductions of 14.6 +/- 14.2/9.9 +/- 6.2 mm Hg were obtained. Full response defined as office DBP reduction of > or = 10 mm Hg from baseline and/or DBP < 90 mm Hg was achieved in 73.3 per cent of cases. Excluding 5 cases of white coat HT diagnosed by 24-h ABPM, full response rate (DBP reduction of > or = 10 mm Hg from baseline and/or < 85 mm Hg) was 76 per cent. Trough to peak ratio and smoothness index for SBP/DBP were highly acceptable (0.75/0.76 and 0.97/1.01, respectively). There were 4 cases of adverse events (2 cases of dizziness, 1 case of headache, and 1 case of acute myocardial infarction).engAdultAngiotensin IIAngiotensin-Converting Enzyme Inhibitors --adverse effectsBenzimidazoles --adverse effectsBenzoates --adverse effectsFemaleHumansHypertension --drug therapyMaleMiddle AgedReceptors, Angiotensin --antagonists & inhibitorsSingle-Blind MethodThailandJournal Article